Explore MCI Treatment Data for LEQEMBI® (lecanemab-irmb)

NOW APPROVED

LEQEMBI^® IQLIK™ once-weekly
at-home subcutaneous injection

After 18 months of treatment
(twice-
monthly infusion), patients can
now
transition to
LEQEMBI IQLIK.¹

Explore dosing

Start LEQEMBI^®. Change the course of AD^1,2

In an 18-month study, LEQEMBI was proven to slow the progression of MCI due to AD and mild AD dementia. Learn more:

Explore the latest data from the Clarity AD trial Learn how to prepare for LEQEMBI Treat and monitor for safety

Learn more about LEQEMBI

LANCE STILL CAN BE LANCE

Empower your patients to take control of AD early and for the long-term to slow disease progression*1,2 *Demonstrated vs placebo through 18 months in Clarity AD; 10 mg/kg infusion once every 2 weeks.1,2

Empower your patients to take control of AD early and for the long-term to slow disease progression*1,2

*Demonstrated vs placebo through 18 months in Clarity AD; 10 mg/kg infusion once every 2 weeks.1,2

Start LEQEMBI®. Change the course of AD1,2

In an 18-month study, LEQEMBI was proven to slow the progression of MCI due to AD and mild AD dementia. Learn more:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA)

INDICATION

CONTRAINDICATION

WARNINGS AND PRECAUTIONS

AMYLOID-RELATED IMAGING ABNORMALITIES

Incidence of ARIA

Incidence of ICH

Risk Factors of ARIA and ICH

ApoE ε4 Carrier Status

Radiographic Findings of CAA

Concomitant Antithrombotic or Thrombolytic Medication

Radiographic Severity With LEQEMBI

Monitoring and Dose Management Guidelines

HYPERSENSITIVITY REACTIONS

INFUSION-RELATED REACTIONS (IRRs)

ADVERSE REACTIONS

LEQEMBI (lecanemab-irmb) is available:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA)

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA)

INDICATION

CONTRAINDICATION

WARNINGS AND PRECAUTIONS

AMYLOID-RELATED IMAGING ABNORMALITIES

Incidence of ARIA

Incidence of ICH

Risk Factors of ARIA and ICH

ApoE ε4 Carrier Status

Radiographic Findings of CAA

Concomitant Antithrombotic or Thrombolytic Medication

Radiographic Severity With LEQEMBI

Monitoring and Dose Management Guidelines

HYPERSENSITIVITY REACTIONS

INFUSION-RELATED REACTIONS (IRRs)

ADVERSE REACTIONS

LEQEMBI (lecanemab-irmb) is available:

You are now leaving LEQEMBIHCP.com

IMPORTANT INFORMATION:

Time to worsening of the global CDR score:

LANCE STILL
CAN BE LANCE

Empower your patients to take control of AD early and for the long-term to slow disease progression^1,2

Demonstrated vs placebo through 18 months in Clarity
AD;
10 mg/kg infusion once every 2 weeks.^1,2

Empower your patients to take control of AD early and for the long-term to slow disease progression*^1,2

*Demonstrated vs placebo through 18 months in Clarity
AD;
10 mg/kg infusion once every 2 weeks.^1,2

Start LEQEMBI^®. Change the course of AD^1,2